Finance

Lists
Why is TCRX down 5.89%?
Dive Deeper
TCRX:NASDAQ
Tscan Therapeutics Inc
$0.22
-5.89%
(-0.014) 1D
Oct 19, 11:30:29 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TCRX...
Open
$0.24
High
$0.24
Low
$0.22
Mkt. cap
14.80M
Avg. vol.
798.32K
Volume
189.67K
52-wk high
$2.55
52-wk low
$0.20
EPS
-$0.91
Beta
1.15
Shares outstanding
63.50M
No. of employees
138
Open
$0.24
High
$0.24
Low
$0.22
Mkt. cap
14.80M
Avg. vol.
798.32K
Volume
189.67K
52-wk high
$2.55
52-wk low
$0.20
EPS
-$0.91
Beta
1.15
Shares outstanding
63.50M
No. of employees
138
News stories
From web sources and news partners
About Tscan Therapeutics Inc
CEO-
Employees138
Founded2018
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitetscan.com
Analyst ratings
Based on 6 analysts giving stock ratings to TCRX in the past 3 months
Hold
Buy
1
Hold
5
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for TCRX in the last 3 months.
Highest
Current $0.22
$1.00 (+359.98%)
Average
$1.00 (+359.98%)
Lowest
$1.00 (+359.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Hold
Downgraded
$1.00
+360%
09/09/2026
Sam Slutsky
LifeSci Capital
Hold
Downgraded
-
-
09/02/2026
Gil Blum
Needham
Hold
Downgraded
-
-
09/02/2026
David Nierengarten
Wedbush
Hold
Downgraded
$1.00
+360%
09/03/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
-
-
08/17/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
08/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.51M
2.57M
982.00K
1.05M
Cost of goods sold
31.69M
18.44M
21.90M
23.40M
Cost of revenue
31.69M
18.44M
21.90M
23.40M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.87M
5.99M
8.22M
8.14M
Operating expense
7.87M
5.99M
8.22M
8.14M
Total operating expenses
39.56M
24.42M
30.12M
31.54M
Operating income
-37.05M
-21.86M
-29.14M
-30.49M
Other non operating income
-
-
-
-
EBT including unusual items
-35.71M
-22.98M
-28.67M
-30.36M
EBT excluding unusual items
-35.71M
-20.98M
-28.67M
-30.36M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-35.71M
-22.98M
-28.67M
-30.36M
Net profit margin
-1,422.14%
-895.09%
-2,919.14%
-2,888.58%
Earnings per share
-0.28
-0.18
-0.22
-0.23
Interest and investment income
2.04M
1.58M
1.16M
833.00K
Interest expense
-699.00K
-702.00K
-689.00K
-699.00K
Net interest expenses
1.34M
881.00K
473.00K
134.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-36.28M
-21.14M
-28.45M
-29.79M
Gain or loss from assets sale
-
-
-
99.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps